Pyk2 promotes neuropeptide‐mediated Src kinase phosphorylation and neuropeptide‐stimulated survival and proliferation of small‐cell lung cancer (SCLC) cells while FAK activity isn't affected by neuropeptides in SCLC cells (Roelle et al., 2008). Here, PTK2 is linked to small cell lung carcinoma.